3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Interventions
Cyclophosphamide
12
Rituximab
10
obinutuzumab
6
fludarabine phosphate
6
Prednisone
6
fludarabine
5
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Melphalan
5
Magnetic Resonance Spectroscopy
5
Lenalidomide
5
Etoposide
5
Biopsy
5
tocilizumab
4
ibrutinib
4
Whole-Body Irradiation
4
Doxorubicin
4
venetoclax
3
polatuzumab vedotin
3
glofitamab
3
Mycophenolic Acid
3
Leukapheresis
3
Filgrastim
3
Cytarabine
3
Cyclosporine
3
Busulfan
3
Bendamustine Hydrochloride
3
ulixertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
cobimetinib
×
30 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled